Latest

Akums Drugs introduces DCGI approved medication for Hypertension

Pharma major Akums Drugs and Pharmaceuticals has introduced Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets, a fixed-dose combination (FDC) medication for the management of uncontrolled essential hypertension with stable coronary artery disease. This FDC integrates the therapeutic benefits of three well-established medications into a single, convenient tablet, offering a comprehensive approach to blood pressure control.

With the approval from the Drugs Controller General of India (DCGI), Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets represent an advancement in cardiovascular care. “This new FDC embodies our commitment to improving patient outcomes and enhancing the quality of life for individuals battling hypertension,” states Sandeep Jain, MD, Akums Drugs and Pharmaceuticals.

Hypertension, a pervasive health challenge associated with significant mortality and long-term morbidity, remains a formidable obstacle in healthcare worldwide. As a major risk factor for vascular diseases such as cerebrovascular disease, ischemic heart disease, cardiac failure, and renal failure, hypertension’s impact on global health cannot be overstated.

By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers, this FDC offers a comprehensive approach to blood pressure control. “We believe that this formulation has the potential to improve the way we manage hypertension” adds Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals.

The individual mechanism of action of each component contributes to the FDC’s efficacy in hypertension management. Amlodipine, by blocking voltage-dependent L-type calcium channels, induces vasodilation and decreases vascular smooth muscle contractility, thereby lowering blood pressure. Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation. Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, reduces cardiac output through negative inotropic and chronotropic effects.

Single-pill triple combinations of different classes of drugs with complementary mechanisms of action help to treat patients to a goal with improved efficacy and better adherence to treatment. Thus, this fixed-dose of triple medications used as a single pill will improve patient’s dose compliance leading to better long-term BP control.

Medlarge

Recent Posts

World Cancer Day 2025: History, significance and all you need to know

Every year on February 4 World Cancer Day is observed to raise awareness of cancer…

22 hours ago

World Cancer Day: Cancer Cases have doubled in India in three decades, says experts

The incidence of cancer has been steadily increasing in India over the last few decades, with the…

23 hours ago

Class 12 student dies of suspected Guillain-Barre Syndrome in Kolkata

A 17-year-old boy died of a suspected case of  Guillain-Barre Syndrome in Kolkata, as multiple…

2 days ago

‘Will prove milestone’, health experts hail budget with focus on Cancer treatment

In a major relief to cancer, rare diseases and other severe chronic diseases, the Union…

3 days ago

Cancer and rare disease drugs go cheaper in Budget 2025

In a major effort to provide relief to patients, particularly those suffering from cancer, rare…

3 days ago

If not dreaming during sleep could be early sign of Alzheimer: Study

People taking longer to enter their 'dreaming' phase of sleep could be experiencing an early…

7 days ago